Wang L, Lu B, He M, Wang Y, Wang Z, Du L (2022) Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Frontiers in public health. 16(10):811044

Article  Google Scholar 

Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A (2020) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77:38–52

Article  PubMed  Google Scholar 

Cantiello F, Crocerossa F, Russo GI et al (2018) Comparison between (64)Cu-PSMA-617 PET/CT and (18)F-Choline PET/CT imaging in early diagnosis of prostate cancer biochemical recurrence. Clin Genitourin Cancer 16:385–391

Article  PubMed  Google Scholar 

Kwee SA, DeGrado T (2008) Prostate biopsy guided by 18F-fluorocholine PET in men with persistently elevated PSA levels. Eur J Nucl Med Mol Imaging. 35:1567–9

Article  PubMed  Google Scholar 

Schmid DT, John H, Zweifel R et al (2005) Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 235:623–628

Article  PubMed  Google Scholar 

Steiner C, Vees H, Zaidi H, Wissmeyer M, Berrebi O, Kossovsky MP, Khan HG, Miralbell R, Ratib O, Buchegger F. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin-NuclearMedicine. 2009;48(01):01-9.

Mapelli P, Panebianco V, Picchio M (2015) Prostate cancer recurrence: can PSA guide imaging? Eur J Nucl Med Mol Imaging 42:1781–1783

Article  CAS  PubMed  Google Scholar 

Castellucci P, Picchio M (2013) 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging 40(Suppl 1):S36-40

Article  PubMed  Google Scholar 

Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM (2013) The role of 11C-Choline and 18F-Fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 64:106–117

Article  PubMed  Google Scholar 

Afshar-Oromieh A, Zechmann CM, Malcher A et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20

Article  CAS  PubMed  Google Scholar 

Paymani Z, Rohringer T, Vali R, Loidl W, Alemohammad N, Geinitz H, Langsteger W, Beheshti M (2020) Diagnostic performance of [18F] Fluorocholine and [68Ga] Ga-PSMA PET/CT in prostate cancer: a comparative study. J Clin Med 9(7):2308

Article  CAS  PubMed  PubMed Central  Google Scholar 

Awwad HM, Geisel J, Obeid R (2012) The role of choline in prostate cancer. Clin Biochem 45:1548–1553

Article  CAS  PubMed  Google Scholar 

Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G (2009) Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 15:167–172

Article  CAS  PubMed  Google Scholar 

Schwenck J, Rempp H, Reischl G et al (2017) Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 44:92–101

Article  CAS  PubMed  Google Scholar 

Deek MP, Tran PT (2020) Oligometastatic and oligoprogression disease and local therapies in prostate cancer. Cancer J 26:137–143

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evangelista L, Bonavina MG, Bombardieri E (2017) Clinical results and economic considerations of (68)Ga-PSMA and radiolabeled choline in prostate cancer. Nucl Med Biol 50:47–49

Article  CAS  PubMed  Google Scholar 

Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gravis G, Boher JM, Chen YH et al (2018) Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 73:847–855

Article  PubMed  PubMed Central  Google Scholar 

Ali SA, Emmett L, Wang J et al (2015) A comparison of the utility of F18 Choline and Ga68 PSMA PET/CT in identifying distant disease in high risk prostate cancer patients being considered for radical prostatectomy. Eur J Nucl Med Mol I 42:S380–S380

Google Scholar 

Alonso O, Dos Santos G, García Fontes M, Balter H, Engler H (2018) 68 Ga-PSMA and 11 C-Choline comparison using a tri-modality PET/CT-MRI (3.0 T) system with a dedicated shuttle. Eur J Hybrid Imag 2:1–6

Google Scholar 

Alonso O, dos Santos G, Fontes MG, Engler H (2016) Prospective comparison of 11C-Choline versus 68Ga-PSMA using a tri-modality PET/CT-MR system for the diagnosis of prostate cancer patients with biochemical recurrence. Journal of Nuclear Medicine 57.

Alonso O, dos Santos G, Fontes MG, Taroco MR, Engler H (2016) Comparison of Ga-68-PSMA and C-11-Choline using a try-modality PET/CT-MR (3.0T) system with a dedicated shuttle. Eur J Nucl Med Mol I 43:S138–S139

Google Scholar 

Argalia G, Tabacchi E, Vichi S et al (2021) [11C]C-Choline, [68Ga]Ga-PSMA, [18F]F-FACBC PET/CT in castration resistant prostate cancer patients: which is the most suitable to assess the therapy response? Eur J Nucl Med Mol I 48:S531–S531

Google Scholar 

Beheshti M, Paymani Z, Geinitz H, Moinfar F, Loidl W, Langsteger W (2018) Ga-68-PSMA-11 PET/CT in assessment of prostate cancer patients - comparison with F-18-Choline PET/CT with regard topatient’s management and therapy monitoring. Eur J Nucl Med Mol I 45:S532–S532

Google Scholar 

Olivier P, Giraudet AL, Skanjeti A et al (2023) Phase III study of (18)F-PSMA-1007 versus (18)F-Fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, crossover multicenter study. J Nucl Med 64:579–585

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morigi JJ, Stricker PD, van Leeuwen PJ et al (2015) Prospective Comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 56:1185–1190

Article  CAS  PubMed  Google Scholar 

Cornford P, Tilki D, van den Bergh RCN, et al. (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Eur Assoc Urol:1–239.

Chondrogiannis S, Marzola MC, Ferretti A et al (2014) Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy? Eur J Nucl Med Mol Imaging 41:1293–1300

Article  CAS  PubMed  Google Scholar 

Beheshti M, Haim S, Zakavi R et al (2013) Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med 54:833–840

Article  CAS  PubMed  Google Scholar 

Urso L, Lancia F, Ortolan N, Frapoli M, Rauso M, Artioli P, Cittanti C, Uccelli L, Frassoldati A, Evangelista L, Bartolomei M (2022) 18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? Clin Transl Imaging 10(6):687–95

Article  PubMed  PubMed Central  Google Scholar 

Ceci F, Herrmann K, Hadaschik B, Castellucci P, Fanti S (2017) Therapy assessment in prostate cancer using choline and PSMA PET/CT. Eur J Nucl Med Mol Imaging 44:78–83

Article  CAS  PubMed  Google Scholar 

Fuccio C, Schiavina R, Castellucci P et al (2011) Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 38:1985–1989

Article  CAS  PubMed  Google Scholar 

Giovacchini G, Picchio M, Coradeschi E et al (2008) [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 35:1065–1073

Article  CAS  PubMed  Google Scholar 

Hara T, Bansal A, DeGrado TR (2006) Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol 33:977–984

Article  CAS  PubMed  Google Scholar 

Pfister D, Porres D, Heidenreich A et al (2016) Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging 43:1410–1417

Article  PubMed  Google Scholar 

Treglia G, Ceriani L, Sadeghi R, Giovacchini G, Giovanella L (2014) Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med 52:725–733